Danimer Scientific, Inc.
DNMR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.83 | -0.23 | -0.96 | 118.76 |
| FCF Yield | -1.80% | -3.13% | -0.78% | -0.07% |
| EV / EBITDA | -46.92 | -72.37 | -361.64 | -43,590.26 |
| Quality | ||||
| ROIC | -18.32% | -26.95% | -10.20% | -3.00% |
| Gross Margin | -57.75% | -14.86% | 1.50% | 24.21% |
| Cash Conversion Ratio | 0.30 | 0.34 | 1.05 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.38% | 3.98% | 22.01% | 15.84% |
| Free Cash Flow Growth | 66.88% | 8.88% | -377.05% | -36.18% |
| Safety | ||||
| Net Debt / EBITDA | -3.63 | -2.43 | -0.01 | 161.71 |
| Interest Coverage | -4.24 | -1.67 | -130.26 | -6.48 |
| Efficiency | ||||
| Inventory Turnover | 2.91 | 1.94 | 2.35 | 2.63 |
| Cash Conversion Cycle | 246.66 | 268.65 | 176.46 | 93.09 |